Williams Cancer Institute

Menu
Menu
Cervical cancer · Interventional immuno-oncology

Your tumor carries viral fingerprints your immune system should see. We unmask them.

For cervical cancer that has come back or spread — we strip away the disguise this virus-driven cancer hides behind, so your immune system can finally see and attack it.

Personalized

Minimally invasive

Immune-activating

Outpatient

In plain terms

What we do, in three paragraphs.

Cervical cancer caught early is often very treatable, but recurrent or metastatic disease is much harder — after the standard immune-and-chemo regimens stop working, options narrow quickly. Our approach treats the tumor directly: ablation plus intratumoral immunotherapy, often using PEF because pelvic tumors sit near the bladder, rectum, and major vessels, where heat-based ablation is risky.
Nearly all cervical cancers are caused by HPV, which means the tumor carries viral proteins (E6 and E7) your immune system should recognize as foreign — but the tumor hides them. Breaking the tumor open exposes those viral “fingerprints” and turns a “cold” tumor “hot”. Injecting immunotherapy into that same spot turns the tumor into a personalized vaccine — AblationVax — aiming for the abscopal effect.
It’s designed for recurrent or metastatic disease progressing after pembrolizumab or cemiplimab + chemotherapy + bevacizumab, or after tisotumab vedotin (Tivdak), and for oligoprogressive disease. We coordinate with your gynecologic-oncology team; most patients finish in about a week as outpatients. Results vary.
One needle, one session: ablation plus immunotherapy delivered where the cancer lives.
AblationVax: the treated tumor teaches your immune system to attack cancer body-wide.
Real outcomes

Stage IV and recurrent disease.

Checkpoint regimens have improved median survival, but most patients still progress — and after tisotumab vedotin, options narrow. Our approach: re-engage immunity through intratumoral delivery + ablation.

Individual results vary. These outcomes represent specific patient cases and are not guaranteed for all patients.

Where our approach fits

Treatment options by stage.

Find your diagnosis below to see what standard care offers, where we add to it, and what role our approach plays.

Early (stage I–IIA)

Standard care
Radical hysterectomy or chemoradiation + brachytherapy.
What we add
Our approach is rarely first-line at this stage.
Standard care first

Locally advanced (IIB–IVA)

Standard care
Concurrent chemoradiation + brachytherapy ± pembrolizumab.
What we add
Intratumoral immune priming in selected cases.
Adjunct to standard care
Our primary focus

Recurrent / metastatic

Standard care
Pembrolizumab + chemo + bevacizumab, then tisotumab vedotin.
What we add
Intratumoral re-engagement after progression.

After standard immune-active lines, repeated IV checkpoint blockade depletes T-cell reservoirs — we deliver stimulation inside the tumor instead.

Systemic immune activation

Oligoprogressive

Standard care
A few growing spots on systemic therapy.
What we add
Local control + intratumoral immune amplification.
Local + systemic strategy
Beyond ablation alone

Destroy the tumor, then teach your immune system to finish the job.

Standard approaches
Our approach — AblationVax
Chemoradiation + brachytherapy ± pembrolizumab; tisotumab vedotin for progression.
Ablation + intratumoral immunotherapy for re-engagement after progression on standard regimens.
IV pembrolizumab: standard systemic exposure.
Delivered directly into the tumor rather than through the bloodstream. The aim is to concentrate treatment at the tumor site and limit whole-body exposure.
Limited options after tisotumab vedotin failure.
Multi-agent intratumoral cocktails as next-line consideration.

Why this approach for cervical cancer?

Treats tumors near critical structures

Pelvic tumors can sit against bladder, rectum, ureters, and iliac vessels. Non-thermal PEF treats where thermal ablation risks bowel or vessel injury.

Converts “cold” tumors into “hot” targets

HPV-driven tumors carry strong viral antigens but suppress the immune response. Ablation + intratumoral immunotherapy overcomes that suppression.

Aims for systemic response

The goal under investigation is to determine whether treating one tumor can help produce a response in untreated metastatic tumors elsewhere in the body—an abscopal response.

Cervical-specific breakthrough

Exploiting HPV-driven antigenicity.

“Cervical cancer is HPV-driven in nearly all cases — tumor cells express viral antigens the immune system can in principle recognize, but typically doesn’t. We deliver immune stimulation right where those viral antigens are most concentrated: inside the tumor.”

— Dr. Jason R. Williams

HPV antigen density

Cervical cancers overexpress E6 / E7 viral oncoproteins — foreign antigens masked by tumor immunosuppression. Ablation releases them; intratumoral immunotherapy amplifies recognition.

Costimulatory + checkpoint combos

OX40 / CD40 agonists complement checkpoint blockade — “step on the gas” plus “remove the brakes” — for patients progressing on pembrolizumab or cemiplimab.

The combination

CpG, OX40 / CD40 agonists, and checkpoint inhibitors delivered together intratumorally can re-establish response in patients who stopped responding to IV blockade.

“HPV-driven cervical cancer should be one of the most responsive to immune approaches — but the tumor microenvironment shuts that down. Intratumoral delivery is how we get around that.” — Dr. Williams

Beyond the procedure: whole-patient support.

We optimize your entire system for the best possible response — and coordinate with the team you already have.

Gut microbiome optimization

Diet, probiotics, and related therapies to support a stronger immunotherapy response.

Off-label protocols

Strategic use of repurposed medications to enhance immune response.

Personalized cocktails

Multi-agent immunotherapy tailored to your specific cancer.

Oncologist coordination

We work alongside your current chemo and radiation team.

What to expect

Your path to treatment.

1

Case review

We review your pelvic MRI, PET-CT, and biomarker reports (PD-L1 CPS, HPV genotype, MSI).

2

Protocol design

A personalized cocktail tuned to HPV status, immune profile, and treatment history.

3

Procedure week

Image-guided ablation + intratumoral immunotherapy. Outpatient.

4

Follow-up

Imaging at 6–8 weeks, coordination with your home team.

Procedure ~1 hour

Recovery ~2 hours

All outpatient

Is this right for you?

You may be a candidate if:

✓Recurrent or metastatic disease progressing on standard sequences
✓Progression after pembrolizumab + chemo + bevacizumab
✓Progression after tisotumab vedotin
✓Oligoprogressive disease on systemic therapy
✓Seeking immune options beyond IV checkpoint blockade

It may not be suitable if:

—Active severe infection
—Pelvic fistula complicating ablation access
—Uncorrectable bleeding disorders
—Very poor performance status (ECOG ≥ 3)
—Diffuse peritoneal pattern without a focal target

Each case is individually evaluated by Dr. Williams’ team.

Track record

Innovation for cervical cancer.

2014

Multi-agent intratumoral protocols developed

The AblationVax concept established across tumor types.

2015

Combination protocols reported

Yervoy / Opdivo / CpG / PV-10 combinations.

Now

Ablation + multi-agent intratumoral protocols

For recurrent and metastatic cervical cancer.

Ready to move forward?

There is more ahead. Take the next step with confidence.

Complimentary evaluation.

Dr. Williams’ team will personally review your case and imaging — no cost, no obligation.

Or email info@williamscancerinstitute.com

Beverly Hills · San Jose del Cabo · Mexico City — most patients complete treatment in one week

Menu

Email Signup